These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35527201)

  • 1. Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3.
    Fainmesser Y; Drory VE; Ben-Shushan S; Lavon A; Spector L; Abramovich B; Abraham A
    Neuromuscul Disord; 2022 Jun; 32(6):451-459. PubMed ID: 35527201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Symptomatic Spinal Muscular Atrophy with Nusinersen: A Prospective Longitudinal Study on Scoliosis Progression.
    Ip HNH; Yu MKL; Wong WHS; Liu A; Kwan KYH; Chan SHS
    J Neuromuscul Dis; 2024; 11(2):349-359. PubMed ID: 38363614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience.
    Łusakowska A; Wójcik A; Frączek A; Aragon-Gawińska K; Potulska-Chromik A; Baranowski P; Nowak R; Rosiak G; Milczarek K; Konecki D; Gierlak-Wójcicka Z; Burlewicz M; Kostera-Pruszczyk A
    Orphanet J Rare Dis; 2023 Aug; 18(1):230. PubMed ID: 37542300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
    Maggi L; Bello L; Bonanno S; Govoni A; Caponnetto C; Passamano L; Grandis M; Trojsi F; Cerri F; Ferraro M; Bozzoni V; Caumo L; Piras R; Tanel R; Saccani E; Meneri M; Vacchiano V; Ricci G; Soraru' G; D'Errico E; Tramacere I; Bortolani S; Pavesi G; Zanin R; Silvestrini M; Politano L; Schenone A; Previtali SC; Berardinelli A; Turri M; Verriello L; Coccia M; Mantegazza R; Liguori R; Filosto M; Marrosu G; Siciliano G; Simone IL; Mongini T; Comi G; Pegoraro E
    J Neurol Neurosurg Psychiatry; 2020 Nov; 91(11):1166-1174. PubMed ID: 32917822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: A retrospective case study with a median 4-year follow-up.
    Funato M; Kino A; Iwata R; Yumioka M; Yamashita K; Urui C; Uno R; Kondo E; Morioka E; Ogawa Y; Kawamura A; Kusukawa T; Minatsu H
    Brain Dev; 2024 Jan; 46(1):62-67. PubMed ID: 37657961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
    Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
    J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nusinersen for adults with spinal muscular atrophy.
    Arslan D; Inan B; Kilinc M; Bekircan-Kurt CE; Erdem-Ozdamar S; Tan E
    Neurol Sci; 2023 Jul; 44(7):2393-2400. PubMed ID: 36854931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
    Hagenacker T; Wurster CD; Günther R; Schreiber-Katz O; Osmanovic A; Petri S; Weiler M; Ziegler A; Kuttler J; Koch JC; Schneider I; Wunderlich G; Schloss N; Lehmann HC; Cordts I; Deschauer M; Lingor P; Kamm C; Stolte B; Pietruck L; Totzeck A; Kizina K; Mönninghoff C; von Velsen O; Ose C; Reichmann H; Forsting M; Pechmann A; Kirschner J; Ludolph AC; Hermann A; Kleinschnitz C
    Lancet Neurol; 2020 Apr; 19(4):317-325. PubMed ID: 32199097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China.
    Li D; Yang J; Wang X; Yang L; Luo R; Huang S
    Brain Behav; 2024 Jul; 14(7):e3630. PubMed ID: 39034388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study.
    Yang H; Tao Q; Li D; Yang J; Cai Q; Gan J; Huang S; Luo R
    BMC Neurol; 2023 Jan; 23(1):35. PubMed ID: 36690929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2.
    Iwayama H; Kawahara K; Takagi M; Numoto S; Azuma Y; Kurahashi H; Yasue Y; Kawajiri H; Yanase A; Ito T; Kimura S; Kumagai T; Okumura A
    Brain Dev; 2023 Feb; 45(2):110-116. PubMed ID: 36335004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nusinersen in adult patients with 5q spinal muscular atrophy: A multicenter observational cohorts' study.
    Vázquez-Costa JF; Povedano M; Nascimiento-Osorio AE; Moreno Escribano A; Kapetanovic Garcia S; Dominguez R; Exposito JM; González L; Marco C; Medina Castillo J; Muelas N; Natera de Benito D; Ñungo Garzón NC; Pitarch Castellano I; Sevilla T; Hervás D
    Eur J Neurol; 2022 Nov; 29(11):3337-3346. PubMed ID: 35872571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and efficacy of a widely available nusinersen program for Polish children with Spinal Muscular Atrophy.
    Kotulska K; Chmielewski D; Mazurkiewicz-Bełdzińska M; Tomaszek K; Pierzchlewicz K; Rabczenko D; Przysło Ł; Biedroń A; Czyżyk E; Steinborn B; Pietruszewski J; Boćkowski L; Cichosz D; Dudzińska M; Gadowska E; Młynarczyk E; Jasiński M; Masztalerz A; Kempisty A; Kostera-Pruszczyk A
    Eur J Paediatr Neurol; 2022 Jul; 39():103-109. PubMed ID: 35738181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results.
    Jiang Y; Wang Y; Xiong H; Li W; Luo R; Chen W; Yin F; Lü J; Liang J; Chen WJ; Lu X; Wang H; Tang J; Monine M; Makepeace C; Jin X; Foster R; Chin R; Berger Z
    Adv Ther; 2024 Jul; 41(7):2743-2756. PubMed ID: 38722537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy.
    Pechmann A; Behrens M; Dörnbrack K; Tassoni A; Stein S; Vogt S; Zöller D; Bernert G; Hagenacker T; Schara-Schmidt U; Schwersenz I; Walter MC; Baumann M; Baumgartner M; Deschauer M; Eisenkölbl A; Flotats-Bastardas M; Hahn A; Horber V; Husain RA; Illsinger S; Johannsen J; Köhler C; Kölbel H; Müller M; von Moers A; Schlachter K; Schreiber G; Schwartz O; Smitka M; Steiner E; Stögmann E; Trollmann R; Vill K; Weiß C; Wiegand G; Ziegler A; Lochmüller H; Kirschner J;
    Brain; 2023 Feb; 146(2):668-677. PubMed ID: 35857854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy.
    Şimşek Erdem N; Güneş Gencer GY; Alaamel A; Uysal H
    Neuromuscul Disord; 2024 Mar; 36():28-32. PubMed ID: 38310720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.